| 000 | 01819 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250515224523.0 | ||
| 264 | 0 | _c20101019 | |
| 008 | 201010s 0 0 eng d | ||
| 022 | _a2151-4658 | ||
| 024 | 7 |
_a10.1002/acr.20211 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBlom, M | |
| 245 | 0 | 0 |
_aFrequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice. _h[electronic resource] |
| 260 |
_bArthritis care & research _cSep 2010 |
||
| 300 |
_a1335-41 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdalimumab |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aAntirheumatic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aArthritis, Rheumatoid _xdrug therapy |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aEtanercept |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin G _xadministration & dosage |
| 650 | 0 | 4 | _aInfliximab |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aOutcome Assessment, Health Care |
| 650 | 0 | 4 |
_aReceptors, Tumor Necrosis Factor _xadministration & dosage |
| 650 | 0 | 4 | _aRegistries |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xantagonists & inhibitors |
| 700 | 1 | _aKievit, W | |
| 700 | 1 | _aKuper, H H | |
| 700 | 1 | _aJansen, T L | |
| 700 | 1 | _aVisser, H | |
| 700 | 1 | _aden Broeder, A A | |
| 700 | 1 | _aBrus, H L M | |
| 700 | 1 | _avan de Laar, M A F J | |
| 700 | 1 | _avan Riel, P L C M | |
| 773 | 0 |
_tArthritis care & research _gvol. 62 _gno. 9 _gp. 1335-41 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/acr.20211 _zAvailable from publisher's website |
| 999 |
_c19858526 _d19858526 |
||